Skip to Content

Prestige Consumer Healthcare Inc PBH

Morningstar Rating
$69.58 −0.28 (0.40%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Price vs Fair Value

PBH is trading at a 2% premium.
Price
$69.58
Fair Value
$59.00
Uncertainty
Medium
1-Star Price
$42.30
5-Star Price
$79.50
Economic Moat
Jgdlgy
Capital Allocation
Grjwkythm

Bulls Say, Bears Say

Bulls

Prestige is well positioned to enjoy macro long-term trends, including aging population, rising awareness of self-care, and premiumization of consumer healthcare.

Bears

Emerging large players in the consumer healthcare space, including Haleon and Kenvue, have the resources to expand their portfolios and displace smaller brands that Prestige owns.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PBH is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$69.86
Day Range
$68.7870.36
52-Week Range
$52.9070.44
Bid/Ask
$56.98 / $111.32
Market Cap
$3.45 Bil
Volume/Avg
100 / 237,964

Key Statistics

Price/Earnings (Normalized)
16.33
Price/Sales
3.05
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
0.72%

Company Profile

Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige’s key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer’s Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Core
Total Number of Employees
560

Competitors

Valuation

Metric
PBH
KVUE
HLN
Price/Earnings (Normalized)
16.3314.3619.00
Price/Book Value
2.163.361.79
Price/Sales
3.052.292.48
Price/Cash Flow
12.1415.0618.00
Price/Earnings
PBH
KVUE
HLN

Financial Strength

Metric
PBH
KVUE
HLN
Quick Ratio
1.870.730.54
Current Ratio
3.091.140.84
Interest Coverage
−0.284.534.10
Quick Ratio
PBH
KVUE
HLN

Profitability

Metric
PBH
KVUE
HLN
Return on Assets (Normalized)
8.80%3.94%3.88%
Return on Equity (Normalized)
19.44%7.85%7.41%
Return on Invested Capital (Normalized)
12.65%6.81%5.99%
Return on Assets
PBH
KVUE
HLN
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
ZTS
Zoetis Inc Class AJyqv$91.5 Bil
MKKGY
Merck KGaA ADRWdfdd$74.9 Bil
HLN
Haleon PLC ADRSlbw$36.8 Bil
VTRS
Viatris IncRzmwk$14.7 Bil
TEVA
Teva Pharmaceutical Industries Ltd ADRBbhzs$14.7 Bil
RDY
Dr Reddy's Laboratories Ltd ADRRlmz$12.9 Bil
CTLT
Catalent IncDnvlbg$10.5 Bil
PRGO
Perrigo Co PLCGdp$3.6 Bil
CURLF
Curaleaf Holdings IncJfvd$3.6 Bil

Sponsor Center